Long COVID has left millions of people with persistent fatigue, brain fog, and inflammatory symptoms that standard treatment approaches haven’t fully resolved. Regenerative medicine is an emerging area of interest for these patients, though it’s important to be clear about what the evidence does and doesn’t yet show.
What Long COVID Involves
Long COVID refers to symptoms that persist for weeks or months after the initial COVID-19 infection has resolved. Common symptoms include persistent fatigue, cognitive difficulties often described as “brain fog,” shortness of breath, and joint or muscle pain. Research increasingly points to sustained immune activation and chronic inflammatory signaling as a central mechanism, rather than ongoing active infection.
This distinguishes long COVID from a typical post-viral recovery, where symptoms resolve as the immune response returns to baseline. In long COVID, some patients show persistent activation of inflammatory pathways well after the virus itself is cleared, which is part of why standard rest-and-recover approaches often aren’t enough.
Why Chronic Inflammation Is the Common Thread
Many of the most disruptive long COVID symptoms are increasingly linked to this sustained inflammatory state rather than direct viral damage. That reframes the treatment question: rather than asking “how do we treat the virus,” the more relevant question for many patients becomes “how do we help the immune system come back down to baseline.”
How UC-MSC Therapy Is Being Studied for Post-Viral Inflammation
UC-MSCs are understood to work partly through immune modulation, secreting anti-inflammatory signaling molecules that may help calm an overactive immune response, a mechanism that’s been studied in other chronic inflammatory and autoimmune contexts. Applying this mechanism to post-viral inflammation and long COVID specifically is an emerging area, and the clinical evidence base here is genuinely earlier-stage than it is for more established applications like joint injuries or autoimmune disease.
At OmniStem, this is approached as a complementary, physician-supervised option for patients who’ve exhausted standard long COVID care pathways and are exploring additional avenues, not as a first-line or standalone treatment for the condition.
Who Might Consider This Option
You may want to discuss this option if:
- You’ve been diagnosed with long COVID by a physician and have persistent symptoms months after infection
- You’ve tried standard long COVID care approaches without full symptom resolution
- You’re interested in exploring immune-modulating approaches under physician supervision
- You’re generally healthy enough to travel for a short treatment stay
This is an emerging application, and our team will speak candidly during your consultation about what the current evidence does and doesn’t support for your specific symptom pattern.
The OmniStem Approach
- Qualify & Prepare — Our team reviews your case and long COVID history; a physician evaluates your symptom pattern and overall health to confirm candidacy before you travel.
- Treatment in Punta Cana — Systemic IV delivery at OmniStem’s own government-regulated facility, licensed by the Dominican Republic’s Ministry of Health, with cells sourced from Wharton’s jelly and full donor-to-patient traceability.
- Monitor & Support — Follow-up tracks your symptom trajectory over time.
Punta Cana is a 90-minute flight from Miami, with direct flights from across the Eastern Seaboard.
Cost
Systemic treatment protocols typically start around $7,000–$8,000. Financing is available for patients who qualify
Educational material only. This article does not replace individualized medical advice, diagnosis, informed consent, or treatment by a qualified physician. Regenerative therapies require medical evaluation. Outcomes vary by patient, condition, and protocol. OmniStem does not diagnose, treat, cure, or guarantee reversal of any disease or symptom. Long COVID applications of UC-MSC therapy represent an emerging and evolving area of research.
